Milk-derived nanoparticles may enable physicians to target aggressive bile duct cancer

Mayo Clinic researchers have developed a promising new way to deliver treatment directly to cholangiocarcinoma tumors, a rare and aggressive bile duct cancer with limited treatment options, using milk-derived nanoparticles that act like guided delivery vehicles. The findings, published in JHEP Reports, point to a potential targeted genetic therapy designed to attack cancer cells while sparing healthy tissue.